IP Library Granted Patent US 8,921,521
Granted Patent B2
US 8,921,521 · App. 13/716,748 · Granted Dec 30, 2014

Macrocyclic modulators of the Ghrelin receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,521
App. No.
13/716,748
Granted
Dec 30, 2014
Kind
B2
Abstract

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Claims (31)

1. A compound of formula W—T—Y, wherein T is selected from the group consisting of the following:

W and Y are independently selected from the group consisting of —OH and —NHR 4 , wherein R 4 is hydrogen or lower alkyl;

L is —CH 2 —or —O—;

Z is halogen or trifluoromethyl;

R 1 is alkyl, substituted alkyl, aryl or substituted aryl;

R 2 and R 3 are independently hydrogen or lower alkyl; and

(W) indicates the point of attachment of T to W; and (Y) indicates the point of attachment of T to Y.

2. The compound of claim 1 further comprising one or more protecting groups.

3. The compound of claim 2 , wherein the protecting group is selected from the group consisting of phthalimido, trichloroacetyl, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), adamantyloxycarbonyl, allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl (Fmoc), α, α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz), tert-butyldimethylsilyl (TBS or TBDMS), tert-butyldiphenylsilyl (TBDPS), tetrahydropyranyl (THP), acetyl (Ac) and benzyl (Bn).

4. The compound of claim 1 having a structure selected from the group consisting of:

5. The compound of claim 4 further comprising one or more protecting groups.

6. The compound of claim 5 , wherein the protecting group is selected from the group consisting of phthalimido, trichloroacetyl, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), adamantyloxycarbonyl, allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl (Fmoc), α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz), tert-butyldimethylsilyl (TBS or TBDMS), tert-butyldiphenylsilyl (TBDPS), tetrahydropyranyl (THP), acetyl (Ac) and benzyl (Bn).

7. The compound of claim 5 having a structure selected from the group consisting of:

8. A method of using a compound of formula W—T—Y of claim 1 as a component in the synthesis of a conformationally-defined macrocyclic compound of the following structure:

wherein the method comprises:

(a) sequentially assembling a building block structure;

(b) attaching the building block structure of (a) to a compound of claim 1 ;

(c) cyclizing the structure of (b) through formation of an intramolecular amide bond; and

(d) optionally removing any protecting group on the structure of (c) to form the structure:

wherein:

BB; is a building block selected from amino acids and hydroxy acids, and n is 1 to 5;

Y 1 ; is —NH—; and

T is selected from the group consisting of the following:

L is —CH 2 —or —O—;

Z is halogen or trifluoromethyl;

R 1 is alkyl, substituted alkyl, aryl or substituted aryl;

R 2 and R 3 are independently hydrogen or lower alkyl; and

(W) indicates the point of attachment of T to NH; and (Y) indicates the point of attachment of T to Y 1 .

9. The method of claim 8 , wherein each BB; is an amino acid and n is 3.

10. The method of claim 8 , wherein the compound of formula W—T—Y used in the synthesis is selected from the group consisting of:

11. The method of claim 8 , wherein the conformationally defined macrocyclic compound is selected from one of the following structures:

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2014
From: TRANZYME PHARMA INC.
To: OCERA THERAPEUTICS, INC.
Reel/Frame 031994/0084 →